The AstraZeneca CGR is building a bespoke database of genomic sequences from samples donated by patients in its global clinical trials. It will analyse over two million genomes in the next 10 years to inform drug discovery and development.
Personalised Healthcare and Biomarkers VP, Ruth March said that Investing in genomics is critical to our continued innovation here at AstraZeneca. The DNAnexus Platform offers a secure, scalable solution that both serves their needs in this pivotal area today and allows them to continue progressing towards their ambitious goal of analysing two million genomes to help them better understand the underlying causes of disease. They look forward to working with DNAnexus to advance the future of personalised healthcare and develop the most innovative and impactful treatments for patients.
DNAnexus CEO, Richard Daly said that the Centre for Genomics Research has established an unprecedented goal of sequencing two million genomes over the course of 10 years, and DNAnexus is pleased to support this important initiative. AstraZeneca is making significant strides towards changing the future of research and development across multiple disease areas, and they are excited to work with their partner to help build their drug discovery and development solution.